Aerska raises $39M Series A to advance RNA therapies for brain disorders
Aerska, a biotechnology company developing RNA-based medicines for central nervous system diseases, has raised $39M in a Series A round to accelerate development of its proprietary brain shuttle platform.

The best Articles in our Network